NamPhuong Tran

2.0k total citations
49 papers, 927 citations indexed

About

NamPhuong Tran is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, NamPhuong Tran has authored 49 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 20 papers in Radiology, Nuclear Medicine and Imaging and 17 papers in Molecular Biology. Recurrent topics in NamPhuong Tran's work include Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (19 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (10 papers). NamPhuong Tran is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (19 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (10 papers). NamPhuong Tran collaborates with scholars based in United States, France and United Kingdom. NamPhuong Tran's co-authors include Karim Fizazi, Thian Kheoh, Milin Acharya, Richard J. Knox, Nobuaki Matsubara, Anil K. Jaiswal, Martha Gonzalez, Kim N., Arturo Molina and Suneel Mundle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

NamPhuong Tran

47 papers receiving 918 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
NamPhuong Tran United States	16	582	313	217	181	177	49	927
Alissa K. Robbins United States	12	261 0.4×	286 0.9×	140 0.6×	118 0.7×	239 1.4×	19	919
Amy H. Tien Canada	14	355 0.6×	296 0.9×	41 0.2×	143 0.8×	89 0.5×	21	709
Paula Kaplan‐Lefko United States	13	345 0.6×	620 2.0×	92 0.4×	99 0.5×	557 3.1×	26	1.3k
Nada Lallous Canada	19	473 0.8×	558 1.8×	61 0.3×	149 0.8×	144 0.8×	40	959
David James VanderWeele United States	15	355 0.6×	485 1.5×	90 0.4×	20 0.1×	300 1.7×	57	1.0k
Shannon C. Dixon United States	14	222 0.4×	452 1.4×	33 0.2×	56 0.3×	216 1.2×	18	844
Mary Jane Staab United States	13	293 0.5×	288 0.9×	67 0.3×	39 0.2×	482 2.7×	24	982
Antonio Hurtado‐Coll Canada	24	1.2k 2.1×	887 2.8×	120 0.6×	191 1.1×	349 2.0×	39	2.0k
Dong Yang China	19	249 0.4×	503 1.6×	34 0.2×	58 0.3×	553 3.1×	53	1.2k
Sarah Sarkar United States	12	137 0.2×	486 1.6×	124 0.6×	21 0.1×	356 2.0×	13	980

Countries citing papers authored by NamPhuong Tran

Since Specialization

Citations

This map shows the geographic impact of NamPhuong Tran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by NamPhuong Tran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites NamPhuong Tran more than expected).

Fields of papers citing papers by NamPhuong Tran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by NamPhuong Tran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by NamPhuong Tran. The network helps show where NamPhuong Tran may publish in the future.

Co-authorship network of co-authors of NamPhuong Tran

This figure shows the co-authorship network connecting the top 25 collaborators of NamPhuong Tran. A scholar is included among the top collaborators of NamPhuong Tran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with NamPhuong Tran. NamPhuong Tran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilson, Brooke E., Andrew J. Armstrong, Johann S. de Bono, et al.. (2022). Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer. 170. 296–304. 20 indexed citations

Minnema, Monique C., Angela Dispenzieri, Giampaolo Merlini, et al.. (2022). Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis. JACC CardioOncology. 4(4). 474–487. 12 indexed citations

Kumar, Shaji, Angela Dispenzieri, Divaya Bhutani, et al.. (2021). OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. Clinical Lymphoma Myeloma & Leukemia. 21. S22–S22. 1 indexed citations

Luo, Man, Peijuan Zhu, Ivo Nnane, et al.. (2021). Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis. The Journal of Clinical Pharmacology. 62(5). 656–669. 8 indexed citations

Grogan, Martha, Matthew J. Maurer, Ronald Witteles, et al.. (2021). EFFECT OF DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE ON CARDIAC FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED AL AMYLOIDOSIS WITH CARDIAC INVOLVEMENT: RESULTS FROM THE PHASE 3 ANDROMEDA STUDY. Journal of the American College of Cardiology. 77(18). 3304–3304. 1 indexed citations

Wechalekar, Ashutosh, Giovanni Palladini, Giampaolo Merlini, et al.. (2020). Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood. 136(Supplement 1). 6–7. 5 indexed citations

Suzuki, Hiroyoshi, Toshitaka Shin, Satoshi Fukasawa, et al.. (2020). Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology. 50(7). 810–820. 35 indexed citations

Matsubara, Nobuaki, Kim N., Mustafa Özgüroğlu, et al.. (2019). Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. European Urology. 77(4). 494–500. 78 indexed citations

Fizazi, Karim, NamPhuong Tran, Luis Fein, et al.. (2019). Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).. Journal of Clinical Oncology. 37(7_suppl). 141–141. 8 indexed citations

10.

Fizazi, Karim, Susan Feyerabend, Nobuaki Matsubara, et al.. (2018). Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.. Journal of Clinical Oncology. 36(15_suppl). 5023–5023. 4 indexed citations

11.

Matsubara, Nobuaki, K.N. Chi, Mustafa Özgüroğlu, et al.. (2018). LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology. 29. viii273–viii274. 4 indexed citations

12.

Fizazi, Karim, NamPhuong Tran, Luis Fein, et al.. (2018). Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.. Journal of Clinical Oncology. 36(6_suppl). 182–182. 7 indexed citations

13.

Fizazi, Karim, NamPhuong Tran, Luis Fein, et al.. (2017). LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. Journal of Clinical Oncology. 35(15_suppl). LBA3–LBA3. 2 indexed citations

14.

Tagawa, Scott T., Edwin M. Posadas, Justine Y. Bruce, et al.. (2016). Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 70(5). 718–721. 15 indexed citations

15.

Montgomery, Bruce, Thian Kheoh, Arturo Molina, et al.. (2014). Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. European Urology. 67(5). 866–873. 44 indexed citations

16.

Tagawa, Scott T., Edwin M. Posadas, Justine Y. Bruce, et al.. (2014). Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 32(15_suppl). 5025–5025. 1 indexed citations

17.

Tran, NamPhuong, et al.. (2013). Mutant strains of Pichia pastoris with enhanced secretion of recombinant proteins. Biotechnology Letters. 35(11). 1925–1935. 21 indexed citations

18.

N., K., Anthony W. Tolcher, Peter P. Lee, et al.. (2012). Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 71(1). 237–244. 28 indexed citations

19.

Acharya, Milin, Martha Gonzalez, Geert Mannens, et al.. (2012). A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica. 43(4). 379–389. 53 indexed citations

20.

Tran, NamPhuong, et al.. (2006). NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochemical Pharmacology. 72(3). 366–376. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact